FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Hill, Mitch C.
2. Issuer Name and Ticker or Trading Symbol

Inari Medical, Inc. [ NARI ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100
3. Date of Earliest Transaction (MM/DD/YYYY)

8/9/2021
(Street)

IRVINE, CA 92618
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 8/9/2021  M  5000.00 A$0.457 72706.00 D  
Common Stock 8/9/2021  S(1)  800.00 D$94.1363 (2)72146.00 (3)D  
Common Stock 8/9/2021  S(1)  3191.00 D$95.1992 (4)68955.00 (3)D  
Common Stock 8/9/2021  S(1)  1009.00 D$95.8365 (5)67946.00 (3)D  
Common Stock         1600.00 I By Spouse 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to buy) $0.457 8/9/2021  M     5000.00   (6)4/30/2029 Common Stock 5000.00 $0.00 286977.00 D  

Explanation of Responses:
(1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2020
(2) This transaction was executed in multiple trades at prices ranging from $93.68 to $94.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(3) Includes 240 shares acquired on July 30, 2021 under the Employee Stock Purchase Plan since the reporting person's last Form 4 filing.
(4) This transaction was executed in multiple trades at prices ranging from $94.68 to $95.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(5) This transaction was executed in multiple trades at prices ranging from $95.68 to $9612. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(6) Options vested with respected with 25% of the shares on April 30,2020 and vested with respect to the remaining shares in 36 equal monthly installment there after.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Hill, Mitch C.
C/O INARI MEDICAL, INC.
9 PARKER, SUITE 100
IRVINE, CA 92618


Chief Financial Officer

Signatures
/s/ Angela Ahmad, attorney-in-fact for Mitch C. Hill8/10/2021
**Signature of Reporting PersonDate

Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Inari Medical Charts.
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Inari Medical Charts.